Epidemiology and Management of ST‐Segment–Elevation Myocardial Infarction in Patients With COVID‐19: A Report From the American Heart Association COVID‐19 Cardiovascular Disease Registry

Author:

Bhatt Ankeet S.1,Varshney Anubodh S.1ORCID,Goodrich Erica L.1ORCID,Gong Jingyi2,Ginder Curtis2,Senman Balimkiz C.2,Johnson Matthew3ORCID,Butler Kayleigh1,Woolley Ann E.4,de Lemos James A.5ORCID,Morrow David A.1ORCID,Bohula Erin A.1ORCID

Affiliation:

1. Levine Cardiac Intensive Care Unit Thrombolysis in Myocardial Infarction (TIMI) Study Group Cardiovascular Division Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA

2. Department of Medicine Brigham and Women’s Hospital and Harvard Medical School Boston MA

3. Harvard Medical School Boston MA

4. Division of Infectious Disease Department of Medicine Brigham and Women’s Hospital and Harvard Medical School Boston MA

5. Division of Cardiology Department of Internal Medicine University of Texas Southwestern Medical Center and Parkland Health and Hospital System Dallas TX

Abstract

Background Early reports from the COVID‐19 pandemic identified coronary thrombosis leading to ST‐segment–elevation myocardial infarction (STEMI) as a complication of COVID‐19 infection. However, the epidemiology of STEMI in patients with COVID‐19 is not well characterized. We sought to determine the incidence, diagnostic and therapeutic approaches, and outcomes in STEMI patients hospitalized for COVID‐19. Methods and Results Patients with data on presentation ECG and in‐hospital myocardial infarction were identified from January 14, 2020 to November 30, 2020, from 105 sites participating in the American Heart Association COVID‐19 Cardiovascular Disease Registry. Patient characteristics, resource use, and clinical outcomes were summarized and compared based on the presence or absence of STEMI. Among 15 621 COVID‐19 hospitalizations, 54 (0.35%) patients experienced in‐hospital STEMI. Among patients with STEMI, the majority (n=40, 74%) underwent transthoracic echocardiography, but only half (n=27, 50%) underwent coronary angiography. Half of all patients with COVID‐19 and STEMI (n=27, 50%) did not undergo any form of primary reperfusion therapy. Rates of all‐cause shock (47% versus 14%), cardiac arrest (22% versus 4.8%), new heart failure (17% versus 1.4%), and need for new renal replacement therapy (11% versus 4.3%) were multifold higher in patients with STEMI compared with those without STEMI ( P <0.050 for all). Rates of in‐hospital death were 41% in patients with STEMI, compared with 16% in those without STEMI ( P <0.001). Conclusions STEMI in hospitalized patients with COVID‐19 is rare but associated with poor in‐hospital outcomes. Rates of coronary angiography and primary reperfusion were low in this population of patients with STEMI and COVID‐19. Adaptations of systems of care to ensure timely contemporary treatment for this population are needed.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3